Emergency Contraception in US Emergency Departments, 2006-2020
Emily L. Vogt,Shani Chibber,Charley Jiang,Rieham Owda,Martina T. Caldwell,Lisa H. Harris,Erica E. Marsh
DOI: https://doi.org/10.1001/jamanetworkopen.2023.53672
2024-01-27
JAMA Network Open
Abstract:Emergency contraception (EC) use increased after US Food and Drug Administration (FDA) approval for over-the-counter (OTC) use for adults on August 24, 2006, and minors in 2013 and the Patient Protection and Affordable Care Act mandate of EC insurance coverage in 2012. 1 Emergency departments (EDs) are important sites for obtaining EC given their 24-hour access and high-acuity care. No study has examined EC-related ED utilization trends despite their utility as a barometer of OTC EC access. We report EC-related ED utilization disparities and associations with EC policy changes. This cross-sectional study analyzed EC-related ED utilization data from 2006 to 2020 from the Nationwide Emergency Department Sample, a database of 2 006 582 771 weighted US ED visits managed by the Healthcare Cost and Utilization Project of the Agency for Healthcare Research and Quality. Females aged 15 to 44 years with an ICD-9 or ICD-10 code of EC were included. Primary outcomes were annual EC-related ED visits and hospital charges with age, income quartile by zip code, hospital geographic region, payment method, and race and ethnicity assessed (eMethods in Supplement 1). We included race and ethnicity data, which were only available from 2019 to 2020, to assess pertinent disparities in EC ED utilization. We also assessed annual ED visits for any non-EC diagnosis to compare trends in overall vs EC-specific ED utilization. This study was exempted by the University of Michigan Institutional Review Board, with informed consent waived for the use of deidentified data. We followed the STROBE reporting guideline. We used SAS, version 9.4 (SAS Institute Inc) and Joinpoint, version 4.7.0.0 (National Cancer Institute) for analysis. We performed a χ 2 test, 2-tailed t test, and 2020 US dollar inflation-adjusted analysis of hospital charge data, with 2-sided P < .05 defined as significant. Missing data were imputed to calculate total charges with age, region, income, and EC-related diagnosis covariates. In total, 47 858 EC-related ED encounters occurred from 2006 to 2020. During this period, EC-related ED encounters decreased by 96%, from 17 019 to 659 ( P < .001) (Figure), and total EC-related hospital charges decreased by 95% ( 7.61 million to $385 946 ( P < .001). The most notable decrease was from 2006 to 2007 and for a primary EC diagnosis. Younger, low-income, Black, Hispanic, and Medicaid-insured females were overrepresented in EC-related vs non-EC ED visits (Table). Northeast hospitals comprised 43.9% to 58.6% of EC-related ED visits despite comprising only 17.1% to 19.1% of non-EC ED visits. Southern hospitals comprised 4.5% to 17.4% of EC-related visits despite consistently averaging more than 40% of non-EC ED visits (Table). Individuals seeking care for sexual assault increased from 0.48% of EC-related ED visits in 2006 to 7.68% in 2020. Our study demonstrates a large decrease in EC-related ED visits and a $7.2 million total annual decrease in hospital charges coinciding with FDA approval (Figure). Although this decrease may have started before 2006, the magnitude of this 2006 to 2007 decline with FDA OTC approval in late August 2006 suggests an association. Our finding that younger, low-income, Medicaid-insured, Black, and Hispanic females are overrepresented in EC-related ED visits aligns with a previous outpatient study 2 and suggests ongoing barriers to OTC EC access and/or increased ED utilization for other reasons, including sexual assault. 3 The steep decrease in privately insured EC ED visits affirms possible income-related disparities. 4 Southern hospitals were disproportionately underrepresented in EC ED visits, aligning with previously defined geographic disparities in OTC EC access. 4 ,5 Study strengths include sample size, national scope, and analysis of insurance and income-related variables and race. Limitations include lack of data before 2006, limited race and ethnicity data, and reliance on ICD codes to approximate services. Increasingly restrictive abortion access will likely drive EC demand to prevent unintended pregnancy. Moreover, disparities in EC-related ED utilization highlight complexities in OTC EC for certain populations. Future policies should reduce barriers to make EC safe and affordable to all. Accepted for Publication: December 6, 2023. Published: January 26, 2024. doi:10.1001/jamanetworkopen.2023.53672 Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2024 Vogt EL et al. JAMA Network Open . Corresponding Author: Erica E. Marsh, MD, MSCI, University of Michigan Medical School, 1500 E Medical Center Dr, University Hospital South, L4000, Ann Arbor, MI 48109 (marshee@med.umich.edu). <strong -Abstract Truncated-
medicine, general & internal